The epidermal growth factor receptor (EGRF) in lung cancer

详细信息    查看全文

• 作者：Enric Carcereny ; Teresa Morán ; Laia Capdevila…
• 关键词：Lung cancer ; Epidermal growth factor receptor ; EGFR ; Tyrosine kinase inhibitors ; TKI
• 刊名：Translational Respiratory Medicine
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：3
• 期：1
• 全文大小：738 KB
• 参考文献：1. Schiller, JH, Harrington, D, Belani, CP, Langer, C, Sandler, A, Krook, J (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: pp. 92-8 CrossRef
  2. Sandler, A, Gray, R, Perry, MC, Brahmer, J, Schiller, JH, Dowlati, A (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: pp. 2542-50 CrossRef
  3. Paz-Ares, LG, Marinis, F, Dediu, M, Thomas, M, Pujol, JL, Bidoli, P (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31: pp. 2895-902 CrossRef
  4. Reungwetwattana, T, Dy, GK (2013) Targeted therapies in development for non-small cell lung cancer. J Carcinog 12: pp. 22 CrossRef
  5. Olayioye, MA, Neve, RM, Lane, HA, Hynes, NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: pp. 3159-67 CrossRef
  6. Normanno, N, Luca, A, Bianco, C, Strizzi, L, Mancino, M, Maiello, MR (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: pp. 2-16 CrossRef
  7. Sergina, NV, Moasser, MM (2007) The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13: pp. 527-34 CrossRef
  8. Herbst, RS, Shin, DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: pp. 1593-611 CrossRef
  9. Raben, D, Helfrich, BA, Chan, D, Johnson, G, Bunn, PA (2002) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29: pp. 37-46 CrossRef
  10. Giaccone, G, Herbst, RS, Manegold, C, Scagliotti, G, Rosell, R, Miller, V (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial -INTACT 1. J Clin Oncol 22: pp. 777-84 CrossRef
  11. Herbst, RS, Giaccone, G, Schiller, JH, Natale, RB, Miller, V, Manegold, C (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial -INTACT 2. J Clin Oncol 22: pp. 785-94 CrossRef
  12. Hidalgo, M, Siu, LL, Nemunaitis, J, Rizzo, J, Hammond, LA, Takimoto, C (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: pp. 3267-79
  13. Herbst, RS, Prager, D, Hermann, R, Fehrenbacher, L, Johnson, BE, Sandler, A (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small- cell lung cancer. J Clin Oncol 23: pp. 5892-9 CrossRef
  14. Gatzemeier, U, Pluzanska, A, Szczesna, A, Kaukel, E, Roubec, J, Rosa, F (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 25: pp. 1545-52 CrossRef
  15. Cappuzzo, F, Ciuleanu, T, Stelmakh, L, Cicenas, S, Szczésna, A, Juhász, E (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo
• 刊物主题：Biomedicine general;
• 出版者：Springer Berlin Heidelberg
• ISSN：2213-0802

文摘

In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.